MICROPHYSIOLOGICAL DRUG-TESTING PLATFORM FOR IDENTIFYING RESPONSES TO PRODRUG TREATMENT IN PRIMARY LEUKEMIA

Furkan Gökçe [1†], Alicia Kaestli [1], Christian Lohasz [1], Martina de Geus [1], Kasper Renggli [1], Beat Bornhauser [2], Andreas Hierlemann [1], and Mario Modena [1]

[1] ETH Zurich, Department of Biosystems Science and Engineering, Basel, Switzerland,

[2] University Children's Hospital Zurich, Children's Research Center, Zurich, Switzerland.

[†] Corresponding author: furkan.gokce@bsse.ethz.ch

Abstract

Despite increasing survival rates of pediatric leukemia patients over the past decades, the outcome of some leukemia subtypes has remained dismal. Drug sensitivity and resistance testing on patient-derived leukemia samples provides important information to tailor treatments for high-risk patients. However, currently used well-based drug screening platforms are severely limited in predicting the effects of prodrugs, a class of therapeutics that require metabolic activation to become effective. To address this limitation, we developed a microphysiological drug-testing platform that enables co-culturing of patient-derived leukemia cells, human bone marrow mesenchymal stromal cells, and human liver microtissues within the same microfluidic platform that, at the same time, regulates the physical interaction between the diverse cell types. Our model recapitulates hepatic prodrug activation of ifosfamide, which cannot be assessed in traditional well-based assays. By testing the susceptibility of primary patient-derived leukemia samples to the prodrug ifosfamide, we identified sample-specific sensitivities to ifosfamide in primary leukemia samples. Our microfluidic platform enables the recapitulation of physiologically relevant conditions and the testing of prodrugs, particularly with short-lived and unstable metabolites, which provides a basis for clinical translation and precision chemotherapy selection.

1. Introduction

Since the initial efforts in the 1940s to 1960s, drug screening for leukemia has heavily relied on high-throughput testing of compound libraries on primary or patient-derived samples, mostly using ex vivo well plate-based assays [1–3]. The prediction of drug efficacy through such tests has led to a massive decrease in mortality of acute lymphoblastic leukemia (ALL) [3]. While cell lines established from primary tumors enabled robust and reproducible protocols for drug development and screening studies, they have been limited to recapitulating specific genetic alterations and have been inadequate in representing the genomic diversity and heterogeneity of primary leukemia cases [4,5]. In addition, some cell lines have been reported to be resistant to anticancer molecules [6], which has further reduced their applicability for drug testing. More recently, the growing clinical interest in genomic profiling of primary leukemia cases has greatly helped to understand the lesions that occur in cancer, especially for pediatric ALL, with implications on treatment identification [7,8]. This improved understanding has led to several functional approaches to develop precision and personalized medicine tools by sequencing and testing primary leukemia cells at single-cell resolution to identify drug response profiles of patients [9–13].

Today, the identification of effective therapeutic approaches for high-risk ALL subtypes is rendered challenging by the lack of representative cell-line models and by the relatively low number of patients having the disease [12]. Disease subtypes are characterized by a variable genetic landscape that is directly affecting the patient responses to treatment, and primary ALL cells can be used to recapitulate the state of the disease of the respective patients in vitro [8,12,13]. Patient-derived xenografts (PDX) have been widely used as in-vivo models to study the biology of leukemia and have been key in leukemia drug-screening studies, as these models feature characteristics that are very similar to those of primary ALL cells. Using patient-derived xenografts, it is possible to generate biobanks for high-throughput testing of patient-derived cells [8,12–16]. The PDX models are generated by collecting leukemia cells from patients via liquid biopsy and injecting the collected primary leukemia cells in immunodeficient mice so that the leukemia cells can proliferate and expand, as illustrated in **Figure 1**.a [14]. The leukemia cells from PDX models (PDX cells) can then be cultured with human bone-marrow-derived mesenchymal cells (MSCs) in serum-free culture medium in well plates and be exposed to anticancer drugs [8,12] (**Figure 1**.b). MSCs enhance the in vitro

viability of PDX cells by secreting essential signaling and growth factors and have been shown not to alter the obtained results with tested compounds [17–19].



Figure 1. *Overview of drug screening experiments using patient-derived xenograft models.* ***a)*** *Summary of the protocol for generating patient-derived xenografts: (1) Selection of patients from high-risk acute lymphoblastic leukemia cases and collection of leukemia cells by liquid biopsy. (2) Injection and expansion of collected leukemia cells in immunodeficient NSG mice. (3) Collection and storage of expanded patient-derived leukemia cells from the spleen of xenografted mice and establishment of a biobank of patient-derived xenograft leukemia (PDX) samples.* ***b)*** *Traditional well-based drug screening, during which the PDX cells from the biobank are cultured in well plates together with human bone-marrow mesenchymal stromal cells (MSCs) and are then exposed to anticancer drugs.* ***c)*** *Assessment of prodrug efficacies in the microphysiological testing platform: (1) Photograph of the platform and (2) cross-sectional view showing the medium reservoirs at each end, interconnected through a microfluidic channel hosting 10 microtissue compartments. (3) Close-up view of one microtissue compartment hosting a human liver microtissue (hLiMT) in an elevated compartment for metabolic transformation of prodrugs as well as MSCs and PDX cells at the bottom of the microfluidic channel.* ***d)*** *Tilting-based operation of the platform for perfusion, i.e., supply of nutrients and transport of metabolites through gravity-driven flow.* ***e)*** *Experimental timeline showing the addition of the distinct cell types to the microfluidic chip, prodrug exposure, and flow-cytometry (FACS) analysis at the end of the experiment after three days of prodrug treatment.*

Well plate-based, high-throughput assays are widely used today in functional precision medicine to test antileukemia efficacies of drug compounds, and robotic handling of assays has allowed for increasing the testing throughput [8,10,12]. However, despite the increased throughput, the overall testing strategy has remained largely unchanged since the 1960s. In these tests, only direct anticancer effects of the compounds are tested, an approach that falls short of recapitulating key physiological phenomena in the body, such as drug metabolic processes that affect drug action and efficacy [20].

Upon administration to a patient, a drug interacts - besides with the target tissue - with many tissue types, through absorption (e.g., in the gut, lung, skin), distribution (e.g., by the blood or interstitial flow), metabolism (e.g., by enzymes in the liver) and excretion (e.g., by the kidney, lung), typically summarized by the acronym ADME [20,21]. For a particular class of drugs, the so-called prodrugs, enzymatic or chemical reactions are required to convert the compounds into their active form [22]. Prodrugs have accounted for over 10% of newly approved therapeutic molecules in the last decade owing to, e.g., their favorable water solubility, improved stability, longer half-life, or better passive permeability [22]. Several prodrugs, such as oxazaphosphorines, have already been proven highly efficacious for leukemia treatment [23]. Many of those prodrugs require metabolic activation by cytochrome P450 (CYP) enzymes that are highly expressed in the liver [22,23]. CYP enzymes are also necessary for the activation and inactivation of both, anticancer drugs and supportive substances or adjuvants [24]. For instance, epipodophyllotoxins and ifosfamide are anticancer drugs that require CYP enzymes for activation, whereas glucocorticoids and vincristine are anticancer drugs that require CYP enzymes to be inactivated [24]. Some prodrugs have stable metabolites, such as irinotecan, and therefore can easily be tested in vitro by exposing the cells directly to their metabolites, such as SN-38, the active metabolite of irinotecan [25]. However, some other prodrugs feature unstable or short-lived metabolites, such as nitrogen mustards, that render in vitro testing particularly challenging [26]. It is, therefore, vital to include prodrugs in drug screening studies and to recapitulate their metabolic activation to effectively assess the impact of short-lived metabolites on leukemia cells.

In this study, we present a microphysiological drug-testing platform featuring the capability to test liver-mediated prodrug transformation on patient-derived leukemia samples. To ensure effective testing with intermediary and final-stage metabolites of a prodrug producing short-lived metabolites, the leukemia cells need to be cultured in close vicinity to the metabolically active tissue, i.e., liver microtissues. Nevertheless, the leukemia cells and liver microtissues must be kept physically separated during the drug exposure study to avoid confounding effects of direct physical interaction between the different cell types. To this end, we realized a multi-tissue microfluidic platform that enables co-culturing of leukemia cells and liver microtissues relying on tubing- and pump-free medium recirculation. Our platform improves on existing drug screening technology by (1) enabling co-cultures of leukemia cells and liver microtissues under conditions of minimized direct physical interaction in the same system to recapitulate hepatic drug

metabolism and by (2) enabling continuous medium perfusion in the system through gravity-driven flow. The latter is necessary to establish stable and reproducible conditions and to avoid diffusion-limitation in the transport of signaling molecules and drug metabolites.

We first characterized our platform and then executed proof-of-concept experiments to test the susceptibility of primary leukemia cells to the prodrug ifosfamide. We used patient-derived xenograft (PDX) models of standard- and high-risk cytogenetic subtypes of pediatric acute lymphoblastic leukemia (ALL) as test samples. We screened multiple patient-derived samples and found that the efficacy of ifosfamide through hepatic activation by the liver microtissues and production of short-lived metabolites could be assessed in our platform. Moreover, we were able to identify and distinguish patient samples that responded to metabolized ifosfamide treatment from those that did not, which was not possible with well plate-based screening assays.

2. Results

2.1. Establishing the platform for ex vivo testing of prodrugs

We developed a platform with medium reservoirs at each end of a microfluidic channel hosting 10 microtissue compartments (**Figure 1**.c). Four of these microtissue compartments represented a metabolic unit and each of them harbored a human liver microtissue (hLiMT) (**Supplementary Figure 1**), while the microfluidic channel was used to culture PDX cells and the MSC feeder layer (**Figure 1**.c). Each chip contained two parallel microfluidic networks and featured standard microscopy slide dimensions for straightforward integration with existing microscopes and chip holders. The platform design was developed on the base of a polystyrene-based microfluidic chip devised by our group [21]. In the new design, the microtissue compartments were elevated by 20 µm with respect to the interconnecting microfluidic channel so as to physically separate microtissues and adherent cells and to hinder PDX cells and MSCs from entering the tissue compartment (**Figure 1**.c, **Supplementary Figure 1**). Tissue-to-tissue or tissue-cell interaction was possible through the common liquid phase and continuous liquid perfusion.

The platform was operated on a tilting device, which generated a gravity-driven flow due to height differences between the two media reservoirs at the ends of the microfluidic channels. The hydraulic pressure difference between the reservoirs induced a pump- and tubing-free perfusion of nutrients and

metabolites inside the channels [21] (**Figure 1**.d). Parallelized experimentation was enabled by stacking multiple platforms and simultaneous operation on a single tilting device (**Supplementary Figure 2**).



Figure 2 *Microscope images showing MSCs, PDX cells, and a hLiMT in our platform three days after seeding MSCs. LEFT: Bright-field, CENTER: GFP, RIGHT: overlay (merged) images.* ***a)*** *MSCs and PDX cells at the bottom of the interconnecting microfluidic channel, showing PDX cells in direct physical interaction with the MSCs.* ***b)*** *MSCs and PDX cells in the compartment where the cells were seeded.* ***c)*** *A hLiMT in the elevated compartment. The elevated platform prevented direct physical interaction between MSCs/PDX cells and hLiMTs by preventing MSCs/PDX cells growing in close proximity to the hLiMTs.*

To perform drug testing including metabolic activity with PDX cells in our platform, we adapted established protocols for well-based drug profiling experiments [8,12]. Drug testing experiments were carried out over 5

days (**Figure 1**.e): MSCs and PDX cells were first seeded in the microfluidic channel during the first two days (Day -1 and -2). On Day 0, the liver microtissues were loaded into the tissue compartments. The prodrug was then added to the system, and all cells were exposed to the test compounds and their metabolites for 3 days. PDX cell viability was assessed at the end of the assay by collecting the cells from the channels and using flow-cytometry analysis.

Microscopy imaging of the chips three days after seeding of the MSCs confirmed that PDX cells and MSCs adhered to the microchannel surface (**Figure 2**.a) and the compartments connected to the cell-loading ports (**Figure 2**.b). MSCs and PDX cells were in direct physical contact, mimicking the standard in-well culture conditions aimed at supporting PDX cell viability. In contrast, very few cells were present in the metabolic compartments, into which the hLiMTs were loaded (**Figure 2**.c). The images validated the function of the elevated stage in the compartment to physically separate hLiMTs and the MSC/PDX co-culture during the assay.

2.2. Characterization of liver metabolism and bioactivation of ifosfamide

To recapitulate hepatic drug metabolism in vitro, we used commercially available human liver microtissues (hLiMTs, InSphero AG, Schlieren, Switzerland) formed from primary hepatocytes. As a test compound, we used the prodrug ifosfamide, an oxazophosphorine, which was specifically designed to require cytochrome P450 (CYP) activation for the generation of highly active but short-lived metabolites that attack DNA molecules in target cancer cells [23,26]. Ifosfamide is metabolized mainly by the CYP3A4 and CYP2B6 enzymes to 4-hydroxyifosfamide (IF-OH), which, after a cascade of biochemical reactions, finally decays inside leukemia cells to the toxic agent of interest, isophospharamide mustard (iso-PM) (**Figure 3**.a) [23,27,28].

To validate the hLiMT ability to metabolize ifosfamide, we exposed the microtissues in well plates to 1 mM ifosfamide and measured the production of ifosfamide metabolites over 72 h by using mass spectrometry (MS). Our results confirmed the production of several metabolites of ifosfamide via liver-mediated transformation including alco-ifosfamide and 2-dichloroethylifosfamide (**Figure 3**.b). Alco-ifosfamide is a metabolite of the drug-activation pathway of ifosfamide, whereas 2-dichloroethylifosfamide is a metabolite of the drug-deactivation pathway [23,28]. Production of both metabolites confirmed and validated the capability of hLiMTs to recapitulate liver-mediated prodrug transformation in vitro. The metabolite

concentrations showed a linear increase throughout 72 hours. To confirm that metabolites were a product of liver transformation, we exposed the hLiMTs to both ifosfamide and ritonavir, a known CYP3A4 inhibitor [29]. The presence of ritonavir in the system resulted in drastically lower concentrations of ifosfamide metabolites in comparison to wells with ifosfamide only (**Supplementary Figure 3**).



Figure 3. *Characterization of the liver metabolism for prodrug transformation.* ***a)*** *Metabolic pathway for transformation of ifosfamide by the cytochrome P450 system in the liver and contribution of CYP3A4 in comparison to other CYP enzymes. Ifosfamide is first hydroxylated by the P450 system to 4-hydroxyifosfamide (IF-OH) that is in equilibrium with its tautomer aldo-ifosfamide (aldo-IF), which spontaneously decays inside leukemia cells to the active form of interest, isophospharamide mustard (iso-PM) a DNA-crosslinking agent, which is toxic for fast-dividing cells.* ***b)*** *Quantification of ifosfamide metabolites generated by human liver microtissues in culture well plates by mass spectrometry (n=2). Concentrations were monitored over 72 h at intervals of 24 h.* ***c)*** *Measured CYP3A4 activity in a well plate and in our platform using a P450-Glo CYP3A4 Assay. LEFT: D-luciferin production per hour by human liver microtissues in individual wells after 72 h, with and without induction with 1 mM ifosfamide before CYP3A4 assay (n=8 for well plate measurements). *** P<0.0001, analyzed using a two-tailed unpaired t-test (Welch's t-test). RIGHT: D-luciferin production per hour and tissue of four human liver microtissues in monocultures or co-culture with 10k MSCs in our platform after 72 h (n=4 for each on-chip condition). All microtissues for on-chip measurements were induced by incubating in 1 mM ifosfamide solution for 24 h before the assay. D-luciferin production was normalized to the number of MTs.*

Next, we characterized the CYP3A4 activity in standard well plates and on-chip by measuring the average conversion of Luciferin-IPA to D-luciferin per hour per microtissue. We first investigated the effect of inducing the metabolic activity of hLiMTs by administering 1 mM ifosfamide. We observed that a 24-h treatment of hLiMTs with the drug solution resulted in a more than 2-fold average CYP3A4 activity during 72 h (**Figure 3**.c), from 4.54 ± 0.12 amol/h D-luciferin for non-induced tissues to 11.46 ± 0.77 amol/h for induced ones (P<0.0001). We then cultured previously induced hLiMTs on-chip (4 hLiMTs per channel)

for 3 days either in monoculture or in co-culture with 10k MSCs. Our measurements showed no significant difference in CYP3A4 activity for the two conditions (9.35 ± 2.19 amol/h per microtissue and 7.56 ± 0.72 amol/h per microtissue, respectively) and with respect to the induced hLiMTs in the well plate ($P>0.05$). We also observed CYP3A4 activity for monoculture of 10k MSCs on-chip when no PDX cells or hLiMTs were present in the channels, however at a lower rate than when hLiMTs were present in the chip (**Supplementary Figure 4**).

2.3. On-chip and well-based prodrug-testing assay

To test ifosfamide on patient-derived samples, the PDX cells and MSCs were co-cultured with hLiMTs (**Figure 2**). The system was exposed to different concentrations of ifosfamide, as illustrated in **Supplementary Figure 1**. To compare the results achieved with our platform to those obtained with well-based assays, we tested the PDX cells in parallel with our system and in a well plate. To recapitulate liver metabolism in the well plate-based assay, we added hLiMTs to separate culturing wells with different ifosfamide concentrations and incubated them for 24 hours. The conditioned medium in hLiMT wells potentially containing metabolites was then transferred into wells with PDX cells (**Supplementary Figure 1**.a, **Supplementary Figure 5**). We decided not to co-culture hLiMTs with PDX samples in the same well to prevent direct physical interaction between liver microtissues and PDX cells or MSCs. Co-culturing of hLiMTs with MSCs in direct contact in a standard well plate would result in MSCs physically attaching to the hLiMTs, partially covering the surface and merging with the microtissues, which would change the CYP3A4 activity of hLiMTs and the viability of PDX cells. Cell collection for the off-chip viability assessment at the end of the assay would also be hindered by physical interaction between the liver microtissues and PDX cells. Finally, we used the same number of initially seeded MSCs and PDX cells, namely 10k MSCs and 100k PDX cells, both in wells and on chips (**Supplementary Figure 1**.b).

We first sought to monitor the viability of PDX cells upon culturing on different materials, in different chip designs, and for using different surface treatments (**Supplementary Figure 6**). Our results showed that the donor cells of PDX-1, derived from a high-risk leukemia patient, featured viability of ~80% on fibronectin-coated channels in the microfluidic chip, which was slightly lower than that of standard culturing in tissue-culture wells. We then exposed cells from the same donor to four concentrations of ifosfamide

(0.01, 0.1, 1, and 10 mM) in standard wells to evaluate the cytotoxicity of the compound (**Supplementary Figure 7**). We also confirmed that ifosfamide exposure did not affect MSC viability, which would otherwise result in a non-specific response of tested samples to the drug compound (**Supplementary Figure 8**). Cell viability was measured after a 3-day drug-exposure treatment by collecting the cells from each well or channel. The number of alive cells was quantified by FACS analysis after staining the dead cells with propidium iodide (PI) and by normalizing the count of viable cells to that of the control condition (no-drug treatment). Our measurements showed that PDX cells exposed to 10 mM ifosfamide showed zero viability, possibly due to the high cytotoxicity of the prodrug compound. As the maximum plasma concentration (C_{max}) of ifosfamide at the highest clinically recommended dose has been reported to be 431 μM [30], we opted for excluding the 10 mM ifosfamide condition from further experiments and to test prodrug efficacy at concentrations of 0.1 and 1 mM, which had little effect on PDX cell viability and corresponded to clinically relevant prodrug-doses [30].



Figure 4. *Normalized viabilities (as percentage of control conditions) of PDX-1 samples after ifosfamide treatment (0, 0.1, or 1 mM)* ***a)*** *in a well plate with or without 24-h-conditioning of the culture medium and* ***b)*** *in our platform with or without on-chip hLiMT co-culturing. The three ifosfamide concentrations are given at the bottom. After a 3-day treatment, viability decreased for increasing ifosfamide concentrations. The hLiMT metabolism did not cause any significant variation in PDX cell viability neither in wells nor on chips. Cell viability in our platform was similar to that in the well plate. The plotted viabilities are calculated by normalizing the measured number of viable cells for each condition to the average number of viable cells of the controls in the wells (0 mM without liver conditioning) or the chips (0 mM without liver co-culturing). Each data point represents the mean of two technical replicates (n=2) of experimental repetitions of each treatment in the wells or on the chips (n=2).*

We then investigated the effect of hepatic transformation of ifosfamide on cell viability of the PDX-1 cells in the well-plate assay and in our platform by implementing a co-culture with hLiMTs (**Figure 1**c). The resulting viabilities in the well plate were 101.9 ± 3.4%, 84.9 ± 2.9% and 43.9 ± 2.9% for the liver-

conditioned medium in comparison to controls without liver conditioning, which featured viabilities of 100 ± 2.6%, 76.7 ± 2.1% and 35.9 ± 1.8%, for ifosfamide concentrations of 0, 0.1 mM and 1 mM (**Figure 4**.a). With our platform we found viabilities of 102.9 ± 10.5%, 68.1 ± 2.6% and 32.9 ± 0.7% when PDX cells were co-cultured with hLiMTs in comparison to the monoculture case exhibiting viabilities of 100 ± 8.5%, 78.7 ± 0.3% and 27.2 ± 0.2%, for 0, 0.1 mM and 1 mM ifosfamide concentrations (**Figure 4**.b). Comparing the resulting viabilities of the well-based assays and our platform to their controls, neither liver-conditioned medium nor co-cultures with hLiMTs showed any detrimental effect on PDX viability for any of the tested drug concentrations. Moreover, responses of PDX cells to ifosfamide treatment in chips and well plates without liver-mediated metabolic effects showed consistent results between the two platforms, which confirmed the suitability of our platform for PDX-based drug testing (**Supplementary Figure 9**).

2.4. Identifying PDX responses to ifosfamide treatment

After confirming that our platform enabled the co-culturing of PDX leukemia cells and hLiMTs, and that hLiMTs maintained the expression of CYP enzymes for biotransformation of prodrugs (**Figure 3** and **Supplementary Figure 3**), we tested the susceptibilities of four additional patient-derived samples (PDX-2 to PDX-5) to ifosfamide and metabolites in our platform (**Figure 5**). These PDX samples consisted of both, standard-risk and high-risk pediatric leukemia patients (**Supplementary Table 1**). Varied responses to ifosfamide were detected for the different PDX samples, and the addition of ifosfamide generally induced a decrease in cell viability with increasing concentration. In comparison to other samples, PDX-2 showed higher tolerance to ifosfamide treatment in our platform, and the 0.1 mM treatment did not decrease PDX viability significantly (**Figure 5**.a), whereas 1 mM treatment showed a reduction in viability by approximately 50%. PDX-2 cell viability was not altered by co-culturing with hLiMTs in the presence of the prodrug compound. For PDX-3 cells, exposure to 0.1 mM and 1 mM of prodrug solutions massively decreased the viability, independent of the presence of ifosfamide metabolites upon hLiMT transformation (29.7 ± 2.0% and 32.9 ± 8.1% for 0.1 mM exposure, 16.6 ± 4.1% and 43.1 ± 36.3% for 1 mM exposure; with and without liver co-culture, respectively) (**Figure 5**.c). PDX-4 viability was strongly affected by the exposure to ifosfamide, and very low viability (10.7 ± 2.3% with and 19.7 ± 8.0% without liver co-culture) was obtained after exposure to 1 mM ifosfamide, either with or without hLiMTs on-chip (**Figure 5**.d). Moreover, upon exposure to the 0.1 mM concentration of ifosfamide, PDX-4 viability decreased to 22.9 ±

3.7% in the case of co-culturing with hLiMTs, which was considerably lower than the 69.9 ± 23.3% viability for PDX-4 without hLiMT co-culturing (**Figure 5**.d). PDX-4 viabilities in well plates showed similar trends like on chip, but the distinct difference at 0.1 mM upon hLiMT co-culturing (**Figure 5**.d), as compared to culturing without hLiMTs, was not visible for conditioned/unconditioned medium in the well plate (**Figure 5**.e). Finally, PDX-5 showed low in vitro viability and the response to ifosfamide treatment could not be measured, as the low number of viable cells at the end of the assay prevented any reliable data interpretation. Therefore, PDX-5 was excluded from subsequent analysis and discussion (**Supplementary Figure 10**).



Figure 5. *Ifosfamide treatment of PDX samples from different patients (as percentage of control conditions for each PDX sample).* ***a)*** *PDX-2 did not show any effect of on-chip liver metabolic conversion of ifosfamide, and no difference in viability could be observed when the hLiMTs were present in co-culture. The tolerance of PDX-2 to ifosfamide treatment was higher in comparison to other PDX samples.* ***b)*** *The response of PDX-2 to the treatment in wells was similar to that in our platform. The sample viability decreased with increasing ifosfamide concentration, and medium conditioning did not result in a difference in the resulting response.* ***c)*** *Similar to PDX-2, PDX-3 did not show a strong response to ifosfamide metabolites when co-cultured with hLiMTs. The viability decreased with increasing ifosfamide concentration, and exposure to 0.1 mM ifosfamide resulted in a drastic decrease in viability.* ***d)*** *PDX-4 showed an effect of liver metabolism for a 0.1 mM ifosfamide treatment in our platform, and the viability decreased in comparison to an ifosfamide treatment without hLiMT co-culturing.* ***e)*** *Treatment of PDX-4 was repeated in a well plate. The medium preconditioning with liver microtissues did not have any effect, in contrast to the on-chip co-culturing.* ***f)*** *Comparison of on-chip dose-responses of PDX-1 (non-responding to metabolites) and PDX-4 (responding) in our platform when*

the samples were cultured with and without hLiMTs for hepatic activation. Each data point in the bar plots represents the mean of two technical replicates (n=2) of experimental repetitions of each treatment in wells or on chips (n=2). Each marker in the dose-response curve represents the mean of the data points of the bar plots, and error bars indicate the SEM (n=2).

To verify the role of liver metabolism in the viability decrease observed in our platform, we compared the on-chip results for PDX-1, PDX-2, PDX-3, and PDX-4 to those obtained with the well plate-based assay with and without medium conditioning by hLiMTs (**Figure 5**, **Supplementary Figure 11**). The PDX-1 and PDX-2 response to the treatment in the well-plate was similar to its response in our platform: PDX-cell viability decreased with increasing ifosfamide concentrations, and liver conditioning of the medium did not result in a significant difference in the response (**Figure 4**, **Figure 5**.b). However, PDX-2 viability was strongly affected by the exposure to ifosfamide, and low cell viability (16.9 ± 0.8% with and 12.6 ± 0.4% without liver conditioning) was obtained after exposure to 1 mM ifosfamide. PDX-3 showed low in vitro viability in the well plate, and the response to ifosfamide treatment could not be reliably measured (**Supplementary Figure 11**).

For PDX-4, exposure to 1 mM ifosfamide in the well plate was toxic to the cells, and no difference in viability was noticed upon medium conditioning. The viability of PDX-4 cells under 0.1 mM ifosfamide exposure was reduced by approximately 30% over the three-day exposure, similar to the viability decrease that was seen for the on-chip assay without hLiMTs. The well plate-based assay showed no difference in cell viability between standard medium and liver-conditioned medium for the 0.1 mM ifosfamide concentration. In contrast, we observed an approximately 80% decrease in cell viability for the on-chip co-culture experiment with hLiMTs as compared to PDX-4 samples without hLiMTs.

For a direct comparison, on-chip dose-response curves of PDX-1 and PDX-4 samples have been plotted in **Figure 5**.f and **Supplementary Figure 12**, which show data with and without co-culturing of hLiMTs. For PDX-1, on-chip co-culturing with hLiMTs did not affect viability, while, in contrast, the viability of the PDX-4 in on-chip co-culture with hLiMTs (i.e., with the continuous metabolic transformation of ifosfamide) was significantly lower in comparison to the same treatment without hLiMT co-culture. It looks like the PDX-4 response to ifosfamide treatment included a prodrug metabolization by the liver microtissues. For the PDX-1 and PDX-4 samples without the presence of hLiMTs/liver medium conditioning, we obtained comparable results in well plates and in our microfluidic platform (**Supplementary Figure 9**).

3. Discussion

In an effort to identify therapeutic strategies for improving the survival rate for leukemia patients, drug screening using patient-derived leukemia cells has enabled to measure the susceptibility of primary leukemia cells to common anticancer compounds and repurposed drugs. However, in vitro drug screening has usually been limited to the detection of direct compound effects. Complex drug effects, such as liver-mediated metabolic conversion of compounds, e.g., prodrugs are only rarely assessed. Therefore, we developed a microfluidic drug-testing platform for co-culturing of patient-derived leukemia cells and human liver microtissues with the aim to include hepatic transformation and prodrugs into overall efficacy testing.

We used human liver microtissues, formed from primary cells of multiple donors, to recapitulate the CYP-mediated metabolism of prodrugs in vitro (**Figure 3**). The use of multi-donor tissues provides consistency over multiple experiments in comparison to single-donor tissues, which usually show a high level of inter-donor variability according to the donor CYP activities [31]. Consistent liver metabolism across experiments was crucial for our proof-of-concept experiments to identify and distinguish responses of patient-derived PDX cells. Mass-spectrometry measurements showed that the hLiMTs were able to metabolize ifosfamide and that the biotransformation of the prodrug was driven by the liver-specific CYP enzymes. The capacity of hepatic biotransformation could further be increased by 24-h induction of the liver microtissues in 1mM ifosfamide solutions prior to exposing the PDX cells to the drug compound. This procedure allowed us to avoid high prodrug concentrations (higher than 1 mM), which were shown to affect PDX viability. The CYP activity of the hLiMTs was confirmed both for static, well plate-based cultures and for on-chip co-culturing conditions. CYP enzymes, especially CYP3A4, have been reported to be expressed by bone marrow stroma and are thought to play a key role in clinical drug resistance through chemoprotection [32,33]. In line with this concept, we observed CYP3A4 activity by the MSC feeder layer when cultured alone on-chip, however, 2-fold lower than the CYP3A4 activity of hLiMTs (**Supplementary Figure 4**).

In this proof-of-principle study, we tested our platform with 5 PDX samples from standard- and high-risk pediatric ALL patients (**Supplementary Table 1**). We characterized the compatibility of the microfluidic platform and established the on-chip prodrug testing assay with ifosfamide using the PDX-1 sample. In addition to PDX-1, four more PDX samples (PDX-2, PDX-3, PDX-4, and PDX-5) were used to test

ifosfamide treatment on chip with the established assay. One sample, PDX-5, showed low in-vitro viability and was, therefore, excluded from further analysis. Ifosfamide treatment for all PDX samples (PDX1, PDX-2, PDX-3, and PDX-4) was carried out in parallel in well plates to elucidate the role of short-lived liver metabolites in the response profiles of these samples. The PDX-3 sample showed low viability in the well-plate assay and was excluded from further analysis.

A comparison of PDX-1 responses without liver-mediated transformation of ifosfamide, i.e., without liver medium conditioning or on-chip hLiMT co-culturing, between the standard well-plate assay and on-chip testing confirmed that the culturing of PDX cells in our microfluidic platform did not affect or alter cell viability or the outcome of the drug-response-profiling experiments (**Supplementary Figure 9**). Cell viability was measured after three days in culture, both on-chip and in standard well plates, using FACS analysis. No difference in relative PDX viability between PDX/MSC and hLiMT co-cultures (or medium conditioning in case of the well-plate assay) and PDX/MSC monocultures could be observed under control conditions, which showed that liver microtissues did not affect PDX viability. The obtained results indicated that PDX-1 did not show a pronounced response to ifosfamide metabolites. Although the absolute number of viable cells in the microfluidic platform after 3 days was lower in comparison to that in the well plate, the relative viabilities and measured responses of PDX-1 cells showed very good agreement between the two culturing methods for all tested ifosfamide concentrations (**Figure 4**, **Supplementary Figure 6**). The agreement in experimental outcome between the two assay types, microfluidic platform and well plate, evidenced that our system could replicate drug responses obtained with traditional well plate-based assays.

Upon testing the other PDX samples on our platform (**Figure 5**, **Supplementary Figure 10**), we observed varying viability. Such variation between PDX samples has already been reported in the literature as optimal culture conditions are patient-dependent and may, therefore, differ for PDX samples from different patients [8,34]. Two of the samples, PDX-2 and PDX-3, did also not show a detectable response to liver-induced ifosfamide metabolites upon treatment in co-culture with liver microtissues, similar to PDX-1. However, ifosfamide exposure decreased the viability of PDX-1, PDX-2, and PDX-3 to a different extent upon increasing concentration, which is a hint that PDX samples of individual patients feature different susceptibilities to the drug compound. In contrast, the PDX-4 sample in co-culture with hLiMTs showed a

much lower viability value upon exposure to 0.1 mM ifosfamide in comparison to an exposure in a monoculture without hLiMTs. The drastic decrease in cell viability suggests a high susceptibility of PDX-4 to ifosfamide metabolites, produced by the hLiMTs on-chip, which is clearly different from the results obtained for the other PDX samples. In the well-plate assay, in comparison, PDX-4 cell viability at 0.1 mM ifosfamide concentration did not show any difference between ifosfamide exposures with and without medium-conditioning by liver microtissues. The strongly decreased viability of PDX-4 cells in co-culture with hLiMTs points to a response of the PDX cells to highly toxic liver-produced metabolites of ifosfamide, such as isophospharamide mustard [23,28]. These metabolites are known to be unstable and short-lived in aqueous solutions and decay within a few hours [23,26]. Therefore, only direct interaction and co-culturing with liver microtissues in the same liquid phase yields this cytotoxic effect of short-lived, liver-metabolism-induced prodrug metabolites, while the conditioning of medium through liver microtissues and a subsequent transfer to target PDX cells is not suitable to recapitulate this effect.

In the microfluidic chips, PDX samples featured, typically, lower viability in comparison to the well-based assay (**Supplementary Figure 6**). We suspect that this effect could be an artifact or a consequence of tedious cell retrieval from the hardly accessible channel regions of the microfluidic chips. Potentially stressful washing and cell retrieval steps were required to collect the cells from the microfluidic channels, which was not the case for standard well plate assays. Moreover, the experimental protocol required a multiplicity of manual pipetting steps to prepare, seed, collect and analyze samples with relatively long waiting times in between, which limited the overall throughput of the study.

In this study, we focused specifically on the possibility to recapitulate the metabolic transformation of prodrugs with the developed platform and investigated the response of PDX samples to short-lived metabolites of ifosfamide. At very high concentrations, MSCs might contribute to reducing PDX viability by transforming ifosfamide through self-expressed CYP-enzymes. However, such high concentrations exceed the reported maximum plasma concentration (C_{max}) of ifosfamide in patients at the highest clinically recommended dose [30]. At clinically relevant concentrations, metabolic transformation only happened through the hLiMTs in co-culture, which could be captured in our platform but not in well plates.

The screening of patient primary leukemia cells with potential chemotherapeutic agents after diagnosis has been reported to improve clinical outcomes [11]. Our platform enables the inclusion of prodrugs and the corresponding short-lived metabolites in functional precision-medicine assays. In addition, co-cultures with metabolically active liver models during drug testing opens a route to investigating other metabolism-induced effects during drug administration. For instance, a system similar to our microfluidic platform was used to recapitulate in vitro drug-drug interaction phenomena and how those can cause drastic variations in drug efficacy [35]. Cancer patients are usually treated with a combination of anti-cancer compounds [2,3]. Our platform could be used for testing of combination therapies on patient-derived or primary samples from high-risk ALL patients. Advanced microfluidic systems could also be used for establishing personalized treatments by including hepatic metabolism and the co-administration of multiple drug compounds into drug testing and screening.

4. Conclusions

We developed and tested a physiologically relevant platform that enables testing of compounds including prodrugs that produce short-lived or unstable metabolites with patient-derived leukemia cells, which is currently not possible using standard well-plate-based testing. Our platform allows for ex-vivo testing of patient-derived leukemia samples in co-culture with and in close vicinity to human liver microtissues in the same microfluidic network. As it offers the possibility to test liver-mediated activation of prodrugs, the developed platform offers great potential for translation to clinical settings for the selection and optimization of treatments of leukemia patients.

While the current chip design allows for testing of up to eight conditions per plate in parallel, the throughput can be increased by modifying the microfluidic network so as to reduce the culture and sample volume. Such design modifications would enable testing a higher number of conditions, however without requiring larger PDX cell numbers. Additional optimization of the chip design could be performed to enable automated imaging-based viability assessment to shorten analysis time and to decrease the complexity of the sample preparation. Nevertheless, the design presented here offers the inclusion of liver metabolism in drug testing for personalized and individual testing of patient-derived PDX ALL cells, which represents

an important advancement in vitro testing, in particular with respect to the broad use of prodrugs, such as oxazaphosphorines that are characterized by short-lived metabolites, in leukemia treatments.

5. Materials and Methods

5.1. Cell Culture

PDXs were generated by injecting in NSG mice primary human ALL cells, recovered from bone marrow aspirates of patients in the ALL-BFM 2000, ALL-BFM 2009, and ALL-REZ-BFM 2002 studies (informed consent was given according to the Declaration of Helsinki and ethics commission of the Canton of Zurich, approval number 2014-0383), as previously described [14]. The samples were classified as standard-risk (SR) or high-risk (HR) according to the ALL-BFM 2000 stratification (**Supplementary Table 1**) [36]. PDX cells were cryopreserved as anonymized vials of 10 to 50 million PDX-ALL cells. The PDX cells were thawed and seeded into the microfluidic channels or in the wells to start the drug exposure tests. More information on the thawing, seeding, and medium conditions for the PDX ALL cells is reported below.

Primary human liver microtissues (3D InSight™ Human Liver Microtissues of multi-donor primary human hepatocytes, XL size production MT-02-302-11, InSphero AG, Schlieren, Switzerland) were cultured using 3D InSight™ Human Liver Maintenance Media - AF (InSphero AG) in Akura96 Ultra-Low Attachment plates (InSphero AG). For PDX-testing experiments, the microtissues were used within 3 days of delivery.

GFP-expressing, hTERT-immortalized primary human bone marrow mesenchymal stromal cells (MSCs) [12,18,19] were kindly provided by D. Campana (St Jude Children's Research Hospital, Memphis, Tennessee). MSCs were maintained in RPMI 1640 medium (Sigma-Aldrich, Buchs, Switzerland) containing 10% fetal bovine serum (Sigma-Aldrich), 2 mM L-glutamine (Thermo Fisher Scientific, Reinach, Switzerland), 100 IU/mL penicillin/streptomycin, and 1 μM hydrocortisone (Sigma-Aldrich).

5.2. Microfluidic Platform Fabrication and Operation

5.2.1. Platform Assembly

The drug-screening platform was developed on the base of an injection-molded, microfluidic multi-tissue culture chip made of polystyrene, which had been previously designed by our group in collaboration with

InSphero AG (AkuraFlow chips) [21]. The microfluidic channels of the chip were modified so as to realize elevated compartments for culturing the liver microtissues and reduce the direct physical interaction of PDX cells and MSCs with the liver microtissues. The elevated platforms were realized by bonding a modified PDMS bottom to the polystyrene chip. We designed the master mold for the PDMS bottom on AutoCAD (Autodesk Inc., Mill Valley, CA, USA); transparency photomasks were printed by Micro Lithographic Services Ltd (Chelmsford, UK). The master mold was fabricated on a 4-inch silicon wafer with SU8-3025 by using standard photolithography steps. The thickness of the SU8-3025 structures was 20 µm. The master mold was then silanized in a vacuum desiccator with Trichloro(1H,1H,2H,2H-perfluorooctyl)silane (Sigma-Aldrich,) for 2 hours. 1:10 PDMS (Sylgard® 184, Sigma-Aldrich) was cast on the master mold and cured at 80ºC for 2 hours. Cut-outs of the cured PDMS slab, which then formed the bottom of our platform, were cleaned from debris using scotch tape (4.977.763, Lyreco, Dietikon, Switzerland) and stored until assembly with the polystyrene chips.

To prepare the polystyrene parts for assembly, they were cleaned with isopropyl alcohol (IPA) and ethanol and then dried with pressurized air. Next, the chips were treated with oxygen plasma for 30 seconds at 50 W power (Harrick Plasma PDC-002, Harrick Plasma, Ithaca, NY, USA) and subsequently submerged in a solution of 2% Bis[3-(trimethoxysilyl)propyl]amine (Sigma-Aldrich) and 1% DI-water in IPA at 80ºC for 20 minutes following previously published protocols [37]. The chips were then rinsed with IPA, dried in a convection oven at 70ºC for 30 minutes, and then immersed in 70% ethanol in water until bonding to the PDMS bottom parts.

The PDMS parts were treated with oxygen plasma for 30 seconds at 50 W power, aligned, and bonded with the silanized polystyrene chips by using a custom chip aligner made of micromanipulators and a stereomicroscope. The assembled chips were then dried and cured at 70ºC for 2 hours.

5.2.2. Platform Operation on Tilting Device

Following the assembly, the chips were sterilized by spraying with IPA and by exposing them to UV-light for 8 hours in a sterile laminar flow hood. For the experiments, we inserted three of our platforms in rectangular holders with ANSI standard well plate dimensions that could accommodate 4 devices. To avoid

medium evaporation during the experiments approximately 4 ml PBS were filled into the well in the fourth position and the chips were sealed with adhesive films featuring holes to facilitate air exchange.

On-chip flow during drug exposure assays was generated by periodically tilting the chips by a ± 3° angle, with a transition time of 30 seconds from each tilting-end position to the rest position (0° angle) and vice versa, and a waiting time of 10 minutes at each tilting-end position. Four 4-well rectangular dishes could be operated with a single tilting device (GravityFlow, InSphero AG, see **Supplementary Figure 2**).

Experimental Procedure for Drug Response Profiling

5.2.3. Culture and Treatment Media

Serum-free AIM-V medium (12055091, Gibco™ AIM V™ Medium, Thermo Fisher Scientific) was used for culturing the samples and for preparing the drug solutions. Ifosfamide (53358-100MG, Ifosfamide analytical standard, Sigma-Aldrich) stock solutions at 10 mM in AIM-V were freshly prepared and diluted to the dosing concentrations (0.1, 1, and 10 mM) for each experiment. The different ifosfamide solutions were used for hLiMT induction, for generation of the liver-conditioned medium, and as treatment solutions. All medium and coating solutions were warmed up and kept in a warm water bath at 37°C for at least 12 hours before starting the assays to prevent air bubble formation in the microfluidic channels.

5.2.4. Chip and Well Plate Preparation

To promote the adhesion and growth of MSCs on our platform, the channels were coated with 100 µg/mL fibronectin (FC010, Sigma-Aldrich) in DPBS (Thermo Fisher Scientific). 100 µL of the fibronectin solution were added to the chip and incubated for 90 minutes at room temperature. After incubation, the channels were flushed with 100 µL PBS and rinsed three times with DI water. The chips were then stored overnight at 4°C. The morning after, PBS was exchanged with 100 µL of AIM-V medium at 37°C, and the chips were kept in a cell-culture incubator at 37°C, 95% humidity and 5% CO_2 for at least 1 hour until the cell seeding.

5.2.5. Seeding MSCs (Day -2)

Each channel or well was seeded with 10k MSC cells. To promote a uniform distribution of cells in the microchannel, MSCs were suspended at 1 million cells/mL in AIM-V media, and 5 µL of suspension were injected into the second and ninth microtissue compartments. On the well plates, 100 µL of AIM-V medium

and 10 µL of the prepared cell suspension was added to each well (Thermo Scientific Nunc™ F96 MicroWell™ Polystyrene Plate, Thermo Fisher Scientific). The seeded chips and well plates were incubated at 37°C, 95% humidity and 5% CO_2 for 24 hours.

5.2.6. Labeling PDX Cells with CellTrace Violet and Seeding (Day -1)

PDX cells were thawed by placing the vials in a cell-culture incubator at 37°C for 5 minutes and by re-suspending the cells in 5 mL medium. To simplify the FACS analysis at the end of the experiment, PDX cells were labeled with CellTrace Violet dye (CTV; C34557, Thermo Fisher Scientific) according to the manufacturer's protocol. The cells were re-suspended in 12.5 µM CTV solution in PBS and incubated for 20 minutes at 37°C and protected from light. The suspension was then centrifuged for 5 minutes at 200 x g, and PDX cells were suspended to a concentration of 10 million cells/mL in AIM-V.

To seed cells in the microfluidic channel, a total of 10 µL of the prepared suspension was added through the inlets of the second and ninth microtissue compartment, as for the MSC seeding procedure. To seed cells in the well plate, 10 µL of the prepared suspension were added to the wells. The initially seeded number of PDX cells for each sample in this study is reported in **Supplementary Table 1**. The seeded chips and well plate were then placed in a cell-culture incubator at 37°C, 95% humidity and 5% CO_2 for 24 hours before starting the drug treatment and tilting.

5.2.7. Liver-conditioned medium and hLiMT induction (Day -1)

For well plate-based experiments, we conditioned the medium by adding hLiMTs to solutions of 0, 0.1, or 1 mM ifosfamide in AIM-V before treatment of the PDX samples. To be able to compare the well-based screening with the on-chip testing, we used identical medium volumes and numbers of hLiMTs for the two conditions, namely 4 hLiMTs per 200 µL solution per well condition (see **Supplementary Figure 1** and **Supplementary Figure 5**). Two hLiMTs were cultured in each well on an Akura96 well plate for 24 hours in 100 µL ifosfamide solution at different concentrations under standard mammalian cell-culture conditions.

To increase the expression of CYP enzymes, the hLiMTs to be used in co-culture with PDX samples on the chips were induced by culturing them in 1 mM ifosfamide solution in AIM-V for 24 hours under standard mammalian cell-culture conditions.

5.2.8. hLiMT Loading and Starting of Drug Assay (Day 0)

On the day of drug treatment, four hLiMTs were transferred to the four center microtissue compartments of each designated device co-culture channel. The reservoirs and microtissue compartments were then sealed by using custom-cut, pressure-sensitive foils (Z734438, ThermalSeal RTS™ Sealing Films, Sigma-Aldrich) with holes for air exchange and to enable access to the reservoirs for medium exchange, sampling, and drug dosing.

For well plate-based experiments, we exchanged the medium in the target wells that hosted the PDX cells and MSCs with 200 µL of conditioned treatment medium, i.e., 100 µL from two separate liver wells (**Supplementary Figure 1**, **Supplementary Figure 5**). For the standard PDX exposure assay, we transferred 20 µL of 10x stock solutions of ifosfamide in AIM-V into the PDX wells on the treatment well plate and added fresh AIM-V medium to reach a total volume of 200 µL in the well.

For the on-chip assay, we added a total of 20 µL of 10x ifosfamide solutions to the medium reservoirs and added fresh AIM-V medium to reach a total on-chip medium volume of 200 µL. The chips were then loaded onto the GravityFlow tilting device and operated for 72 hours at standard mammalian cell-culture conditions.

5.3. Flow Cytometry Analysis (Day 3)

After 72 hours of treatment, the tilting was stopped, and the chips and wells were removed from the incubator. After collection of the supernatant, each channel and well was washed with 50 µL PBS. Afterward, 100 µL AccuMAX cell detachment solution (Sigma-Aldrich) was added and the chip was incubated at room temperature for ~20 minutes. The cell suspensions were collected, and channels and wells were washed with 50 µL PBS. All washing fractions and the cell suspensions of each well were pooled to ensure complete retrieval of cells.

In a V-bottom well plate, 25 µL of fluorescent counting beads (1 million/mL, 424902, Precision Count Beads, BioLegend, San Diego, California USA) were mixed with 100 µL of cell suspension for each condition, and 1 µL propidium iodide solution (P4864, Sigma- Aldrich, Buchs, Switzerland) was added. For each sample, we performed two technical replicates.

FACS analysis was conducted by using a BD LSRFortessa Cell Analyzer with a high throughput sampler (HTS, BD Biosciences, Allschwil, Switzerland). The recording thresholds and voltages for forward- and side-scattering channels were adapted to the scattering amplitudes of the PDX cells individually for each PDX sample and not to the scattering amplitudes of the MSCs. Five to ten thousand events were recorded per well. CTV (for gating PDX cells) was excited at 405 nm and detected with a 450/50 band-pass filter for emission. GFP (for filtering MSCs and counting fluorescent beads) was excited at 488 nm and detected with a 505 nm long-pass filter, and a 530/30 band-pass filter for emission. PI (for quantifying dead PDX cells) was excited at 561 nm and detected with a 600 nm long-pass filter, and a 610/20 band-pass filter for emission. Flow cytometry data were analyzed by using the FlowJo software (FlowJo, LLC, Ashland, Oregon, USA). The analyses were normalized with respect to the number of counted fluorescent beads and corrected for the total volume in the wells or on chips. The total number of viable cells after 3-day incubation in wells and on chips are reported for each PDX sample in **Supplementary Table 1**. A workflow for flow cytometry analysis of PDX-1 is provided in the Supplementary Material (**Supplementary Figure 13**).

5.4. Mass Spectrometry for Ifosfamide Metabolism

To investigate hepatic bioactivation of ifosfamide, hLiMTs in Akura96 well plates were first induced by exposure to 1 mM ifosfamide in AIM-V. Then, the wells were washed and 25 µL of 1 mM ifosfamide solution in AIM-V were added with or without ritonavir (1 µM, Sigma-Aldrich). 5µL supernatant solutions were collected after 0, 24, 48, and 72 h from individual wells and snap-frozen into AIM-V (45 µL) on dry ice. All samples were frozen and shipped to Admescope Ltd. (Oulu, Finland), where they were semi-quantitatively analyzed by ultra-performance liquid chromatography-mass spectrometry (UPLC–MS). For the mass spectrometry measurements presented in this study, the estimated limit of detection of alco-ifosfamide was 100 nM and that of 2-dichloroethylifosfamide was 200 nM. The plotted data were normalized with respect to the signals of a 1 mM ifosfamide solution measured at the same time intervals with mass spectrometry to compensate for any evaporation effects.

5.5. CYP3A4 Assay

CYP3A4 activity of hLiMTs in monoculture or in co-culture with MSCs was assessed using the P450-Glo CYP3A4 Assay (Promega, Dübendorf, Switzerland) with luciferin isopropyl acetal (luciferin-IPA) as substrate. The activity of individual hLiMTs was measured in static well plates, while the activity of 4 hLiMTs in monoculture or in co-culture with MSCs was measured for in the microfluidic platform and under perfusion.

5.6. Microscopy Imaging

Bright-field images of MTs in well plates were acquired using a Cell3iMager Neo cc-3000 (Screen Holdings Co., Ltd, Kyoto, Japan) to track the loading and retrieval of hLiMTs. Bright-field and fluorescence images of cells and MTs in the microfluidic platform were acquired using an inverted microscope equipped with a CrestOptics X-Light v3 spinning disk confocal (Nikon Eclipse Ti2-E; Nikon Europe B.V., Amsterdam, Netherlands). The images were processed by using ImageJ.

5.7. Statistics and Data Availability

Data sets of FACS analyses were generally presented as individual values (biological replicates, n=2), each representing the average of two technical replicates and by showing their mean values unless otherwise indicated. If no error bar is visible in a figure, it indicates that the error bar is smaller than the size of the symbol. CYP3A4 activity experiments were compared with each other by performing an unpaired t-test with Welch's correction using GraphPad Prism The experimental data presented and discussed in this work are available on request. The data supporting the findings are available within the paper and in the Supplementary Material. The analysis data generated for this study are available from the corresponding author on reasonable request.

Author Contributions

F.G. designed and fabricated the microfluidic devices, designed and performed all experiments, analyzed and interpreted data, and wrote the manuscript. **A.K.** conceived the project, ran initial validation experiments, and edited the manuscript. **C.L.** provided experimental advice, contributed to the MS

experiment and flow cytometry analysis, and edited the manuscript. **M.G.** contributed to the initial validation experiments with A.K. **K.R.** conceived the project, initiated experimental realization and supervised initial experiments. **B.H.** conceived the project, provided cell culture, patient-derived samples, and clinical-relevant advice, and edited the manuscript. **A.H.** provided experimental advice and led the experimental project, edited the manuscript. **M.M.** supervised the project and provided experimental advice, contributed to platform and experiment design, and the MS experiment, and edited the manuscript. All authors discussed the results and implications and commented on the manuscript at all stages.

Competing Interests

The authors have no conflicts to disclose.

Acknowledgments

This work was financially supported by the Personalized Health and Related Technologies (PHRT) initiative of the ETH Domain (Project No. SFA-PHRT-2017-309). We acknowledge Dr. Hans-Michael Kaltenbach for their valuable input on the experiment design, Dr. Olivier Frey, and InSphero AG for providing the Akura™ Flow polystyrene chips and human liver microtissues throughout the experiments, and Jana Petr for their support with confocal imaging of the cell cultures. Further, we thank the flow cytometry team at the D-BSSE Single Cell Facility for their on-site assistance and guidance with analyses. Finally, we acknowledge current and previous members of the Bio Engineering Laboratory at ETH Zurich, and of the Pediatric Oncology Research Group at University Children's Hospital Zürich for their valuable discussions and input on the conducted work.

References

1. Farber, S., Diamond, L. K., Mercer, R. D., Sylvester, R. F. & Wolff, J. A. Temporary Remissions in Acute Leukemia in Children Produced by Folic Acid Antagonist, 4-Aminopteroyl-Glutamic Acid (Aminopterin). *N. Engl. J. Med.* **238**, 787–793 (1948).

2. Chabner, B. A. & Roberts, T. G. Chemotherapy and the war on cancer. *Nat. Rev. Cancer 2005 51* **5**, 65–72 (2005).

3. Hunger, S. P. & Mullighan, C. G. Acute Lymphoblastic Leukemia in Children. *N. Engl. J. Med.* **373**, 1541–1552 (2015).

4. Allen, D. D. *et al.* Cell Lines as In Vitro Models for Drug Screening and Toxicity Studies. *http://dx.doi.org/10.1080/03639040500216246* **31**, 757–768 (2008).

5. Wong, A. H. H. *et al.* Drug screening of cancer cell lines and human primary tumors using droplet microfluidics. *Sci. Reports 2017 71* **7**, 1–15 (2017).

6. Iorio, F. *et al.* A Landscape of Pharmacogenomic Interactions in Cancer. *Cell* **166**, 740–754 (2016).

7. Iacobucci, I., Kimura, S. & Mullighan, C. G. Biologic and Therapeutic Implications of Genomic Alterations in Acute Lymphoblastic Leukemia. *J. Clin. Med. 2021, Vol. 10, Page 3792* **10**, 3792 (2021).

8. Fischer, U. *et al.* Genomics and drug profiling of fatal TCF3-HLFâ ’positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options. *Nat. Genet.* **47**, 1020–1029 (2015).

9. Valent, P. *et al.* Precision Medicine in Hematology 2021: Definitions, Tools, Perspectives, and Open Questions. *HemaSphere* **5**, (2021).

10. Letai, A., Bhola, P. & Welm, A. L. Functional precision oncology: Testing tumors with drugs to identify vulnerabilities and novel combinations. *Cancer Cell* **40**, 26–35 (2022).

11. Kornauth, C. *et al.* Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders. *Cancer Discov.* (2022). doi:10.1158/2159-8290.CD-21-0538

12. Frismantas, V. *et al.* Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia. *Blood* **129**, e26–e37 (2017).

13. Bornhauser, B. C. Chemoresistance and Drug Profiling in ALL. *Clin. Lymphoma Myeloma Leuk.* **21**, S57–S58 (2021).

14. Schmitz, M. *et al.* Xenografts of highly resistant leukemia recapitulate the clonal composition of the leukemogenic compartment. *Blood* **118**, 1854–1864 (2011).

15. Clappier, E. *et al.* Clonal selection in xenografted human T cell acute lymphoblastic leukemia recapitulates gain of malignancy at relapse. *J. Exp. Med.* **208**, 653–661 (2011).

16. Richter-Pechańska, P. *et al.* PDX models recapitulate the genetic and epigenetic landscape of pediatric T-cell leukemia. *EMBO Mol. Med.* **10**, e9443 (2018).

17. Kumagai, M. A. *et al.* Stroma-supported culture of childhood B-lineage acute lymphoblastic leukemia cells predicts treatment outcome. *J. Clin. Invest.* **97**, 755–760 (1996).

18. Mihara, K. *et al.* Development and functional characterization of human bone marrow mesenchymal cells immortalized by enforced expression of telomerase. *Br. J. Haematol.* **120**, 846–849 (2003).

19. Iwamoto, S., Mihara, K., Downing, J. R., Pui, C. H. & Campana, D. Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. *J. Clin. Invest.* **117**, 1049–1057 (2007).

20. Bhatia, S. N. & Ingber, D. E. Microfluidic organs-on-chips. *Nat. Biotechnol.* **32**, 760–772 (2014).

21. Lohasz, C., Rousset, N., Renggli, K., Hierlemann, A. & Frey, O. Scalable Microfluidic Platform for Flexible Configuration of and Experiments with Microtissue Multiorgan Models. *SLAS Technol.* **24**, 79–95 (2019).

22. Rautio, J., Meanwell, N. A., Di, L. & Hageman, M. J. The expanding role of prodrugs in contemporary drug design and development. *Nat. Rev. Drug Discov. 2018 178* **17**, 559–587 (2018).

23. Wang, D. & Wang, H. Oxazaphosphorine bioactivation and detoxification: the role of xenobiotic receptors. *Acta Pharm. Sin. B* **2**, 107–117 (2012).

24. Pui, C.-H., Relling, M. V. & Downing, J. R. Acute Lymphoblastic Leukemia. *N. Engl. J. Med.* **350**, 1535–1548 (2004).

25. Mathijssen, R. H. J. *et al.* Irinotecan pharmacokinetics-pharmacodynamics: the clinical relevance of prolonged exposure to SN-38. *Br. J. Cancer 2002 872* **87**, 144–150 (2002).

26. Bosanquet, A. G. Stability of solutions of antineoplastic agents during preparation and storage for in vitor assays. *Cancer Chemother. Pharmacol.* **14**, 83–95 (1985).

27. Wang, D., Li, L., Fuhrman, J., Ferguson, S. & Wang, H. The role of constitutive androstane receptor in oxazaphosphorine-mediated induction of drug-metabolizing enzymes in human hepatocytes. *Pharm. Res.* **28**, 2034–2044 (2011).

28. Li, F. *et al.* Comparative Metabolism of Cyclophosphamide and Ifosfamide in the Mouse Using UPLC-ESI-QTOFMS-Based Metabolomics. *Biochem. Pharmacol.* **80**, 1063 (2010).

29. Rock, B. M., Hengel, S. M., Rock, D. A., Wienkers, L. C. & Kunze, K. L. Characterization of ritonavir-mediated inactivation of cytochrome P450 3A4. *Mol. Pharmacol.* **86**, 665–674 (2014).

30. Liston, D. R. & Davis, M. Clinically relevant concentrations of anticancer drugs: A guide for nonclinical studies. *Clin. Cancer Res.* **23**, 3489–3498 (2017).

31. Tsamandouras, N. *et al.* Quantitative assessment of population variability in hepatic drug metabolism using a perfused three-dimensional human liver microphysiological system. *J. Pharmacol. Exp. Ther.* **360**, 95–105 (2017).

32. Alonso, S. *et al.* Human bone marrow niche chemoprotection mediated by cytochrome P450 enzymes. *Oncotarget* **6**, 14905–14912 (2015).

33. Chang, Y. T. *et al.* Role of CYP3A4 in bone marrow microenvironment–mediated protection of FLT3/ITD AML from tyrosine kinase inhibitors. *Blood Adv.* **3**, 908–916 (2019).

34. Jiang, Z. *et al.* Defined, serum/feeder-free conditions for expansion and drug screening of primary B-acute lymphoblastic leukemia. *Oncotarget* **8**, 106382–106392 (2017).

35. Lohasz, C. *et al.* Predicting Metabolism-Related Drug–Drug Interactions Using a Microphysiological Multitissue System. *Adv. Biosyst.* **4**, 2000079 (2020).

36. Bonapace, L. *et al.* Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance. *J. Clin. Invest.* **120**, 1310–1323 (2010).

37. Sip, C. G. & Folch, A. Stable chemical bonding of porous membranes and poly(dimethylsiloxane) devices for long-term cell culture. *Biomicrofluidics* **8**, 036504 (2014).